- Conditions
- Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
- Interventions
- Genasense (oblimersen, G3139)
- Drug
- Lead sponsor
- Genta Incorporated
- Industry
- Eligibility
- 18 Weeks and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 6,437
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Highly Sensitized Patients on Waiting List for Kidney Transplantation
- Interventions
- Inebilizumab, VIB4920, Inebilzumab+VIB4920
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- San Diego, California • Bethlehem, Pennsylvania
- Conditions
- Kidney Transplantation
- Interventions
- Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 38
- States / cities
- Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more
- Conditions
- Chronic Kidney Disease, Kidney Transplant, Coronary Microvascular Dysfunction (CMD), Inflammation
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute (Cellular) Renal Allograft Rejection
- Interventions
- rATG
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Erythropoiesis-Stimulating Agent (ESA), Vadadustat
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 18
- States / cities
- Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more
- Conditions
- Tumor
- Interventions
- belinostat, 5-Fluorouracil (5-FU)
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
- Interventions
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Drug
- Lead sponsor
- Ikena Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
- Interventions
- INCAGN02385
- Biological
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- quinacrine
- Drug
- Lead sponsor
- Cleveland BioLabs
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Albany, New York • Charlotte, North Carolina
- Conditions
- SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
- Interventions
- Urine Collection
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan
- Conditions
- Advanced Renal Cell Carcinoma (RCC)
- Interventions
- Pumitamig, Ipilimumab, Cabozantinib, Casdatifan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 17
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
- Conditions
- Sepsis, Acute Kidney Injury
- Interventions
- AZD4144, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Newport Beach, California • Kansas City, Kansas + 11 more
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer
- Interventions
- 23ME-00610
- Drug
- Lead sponsor
- 23andMe, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Not listed
- Lead sponsor
- Lupus Foundation of America
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2050
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Complicated Urinary Tract Infection, Pyelonephritis
- Interventions
- CXA-201, Levofloxacin
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- San Diego, California • Wheat Ridge, Colorado • Hialeah, Florida + 2 more
- Conditions
- Kidney Disease, Kidney Failure, Chronic Kidney Disease
- Interventions
- Surgical fistula creation from patient's anatomy, Surgical Graft implant
- Procedure · Device
- Lead sponsor
- E. Peden, MD
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- BK Virus Infection
- Interventions
- MAU868, Placebo
- Drug · Other
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
- Conditions
- Kidney Disease, Chronic, Endothelial Dysfunction
- Interventions
- Beet It Sport Shot, Nitrate-depleted placebo
- Dietary Supplement
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Chronic Kidney Disease (Stages 1-4)
- Interventions
- CommunityRx-Kidney Health
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Beulaville, North Carolina
- Conditions
- Kidney Transplantation
- Interventions
- Mycophenolate mofetil, Cyclosporine, Tacrolimus
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Fosaprepitant
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hepatic Impairment; Renal Impairment
- Interventions
- Plasma Sampling
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee